Massive blooms of sargassum seaweed are choking Caribbean coastlines – threatening marine life, deterring tourism and damaging coastal economies – but where others see a threat, SOS Biotech is already turning the invasive species into valuable products.
Dr Emily Kostas, a multidisciplinary bioscientist and applied phycologist with over a decade’s experience working with seaweed, offers insights into how biorefineries work, why they matter and what challenges lie ahead.
Bacteriophages are poised to revolutionise aquaculture by significantly reducing mortality rates and antibiotic use, according to Dr Aristobulo Loaiza, CEO of Hedros Bio.
A new business opportunity which will involve the Centre for Aquaculture technologies (CAT) collaborating with Brazilian Fish to grow genome edited tilapia is a promising landmark – both for the companies and for the aquaculture industry as a whole.
AlgiSys BioSciences, which has developed a proprietary strain of microalgae for aquafeeds that’s rich in EPA omega-3 and alternative protein, is currently looking to raise $5 million to enable commercial-scale production.
Umami Bioworks is bucking the negative trends that hit the cell-cultivated meat and seafood sectors – landing significant deals with some of the biggest players in the seafood and pet food worlds.
Recent trials in Thailand suggest that mixed-sex tilapia farming might offer a promising alternative to the cultivation of hormone-induced all-male fish, especially in cage farms in Africa.
Producing sterile animals brings a wide range of advantages over producing fertile ones and genome editing is currently the most promising technique for ensuring that sterilisation is both feasible and effective.
